Navigation Links
Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Date:7/30/2009

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabi
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014   ... life sciences company that provides innovative genetic analysis solutions, ... provider of esoteric laboratory services in the ... for noninvasive prenatal testing patents and applications. ... research, innovation, and patient care, and we welcome the ...
(Date:7/29/2014)... Cat: Can a particle be separated from its properties? ... , published the results of the first Cheshire Cat ... by Chapman University in Orange, CA, and Vienna University ... cat without a grin," thought Alice in Wonderland, "but ... thing I ever saw in my life!" Alice,s surprise ...
(Date:7/29/2014)... A team of researchers has created a new ... three-dimensional textures. These surfaces, made by self-assembly of ... properties including controllable mechanical stiffness and strength, ... certain direction. , "We have demonstrated that mechanical ... form complex three-dimensional microstructures, and that we can ...
(Date:7/29/2014)... July 29, 2014  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: IPXL).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On July 29, 2014, Impax Laboratories, Inc. (the "Company") ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... ... ... September 3, 2009 -- Researchers at the U.S. Department of Energy,s Argonne National ... technique could lead to better biosensors, disease therapeutics and diagnostic reagents and non-laboratory ...
... , NEW YORK, Sept. 3 Reportlinker.com announces that ... , Proteomics: Technologies and Global Markets ... , , REPORT HIGHLIGHTS , ... increase from $6.7 billion in 2008 to an estimated $7.9 billion in ...
... , EMERYVILLE, Calif., Sept. 3 Adamas Pharmaceuticals, ... data will be delivered as an oral presentation during the ... in San Francisco, CA on September 13, 2009. The presentation ... study of Adamas, triple combination antiviral drug (TCAD) therapy. ...
Cached Biology Technology:Argonne Researchers Develop Method that Aims to Stabilize Antibodies 2Argonne Researchers Develop Method that Aims to Stabilize Antibodies 3Argonne Researchers Develop Method that Aims to Stabilize Antibodies 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 2Reportlinker Adds Proteomics: Technologies and Global Markets Report 3Reportlinker Adds Proteomics: Technologies and Global Markets Report 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 5Reportlinker Adds Proteomics: Technologies and Global Markets Report 6Reportlinker Adds Proteomics: Technologies and Global Markets Report 7Reportlinker Adds Proteomics: Technologies and Global Markets Report 8Reportlinker Adds Proteomics: Technologies and Global Markets Report 9Reportlinker Adds Proteomics: Technologies and Global Markets Report 10Reportlinker Adds Proteomics: Technologies and Global Markets Report 11Reportlinker Adds Proteomics: Technologies and Global Markets Report 12Reportlinker Adds Proteomics: Technologies and Global Markets Report 13Reportlinker Adds Proteomics: Technologies and Global Markets Report 14Reportlinker Adds Proteomics: Technologies and Global Markets Report 15Reportlinker Adds Proteomics: Technologies and Global Markets Report 16Reportlinker Adds Proteomics: Technologies and Global Markets Report 17Reportlinker Adds Proteomics: Technologies and Global Markets Report 18Reportlinker Adds Proteomics: Technologies and Global Markets Report 19Reportlinker Adds Proteomics: Technologies and Global Markets Report 20Reportlinker Adds Proteomics: Technologies and Global Markets Report 21Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting 2
(Date:7/29/2014)... 2014 Research and Markets  has announced ... (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies that ... information about a company,s operations. BI help organizations to ... for example, metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... been plaguing the Northern Territories in Canada and have ... the U.S. continue on. NASA,s Aqua satellite collected ... MODIS, instrument on July 26, 2014. Actively burning areas, ... Copious amount of smoke are drifting northward in this ... of Yellowknife. Fire has caused power outages in ...
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
... The treatment of central nervous system (CNS) diseases can ... as recombinant proteins and gene medicines are not easily transported ... to "open the door" of the blood brain barrier. However, ... therapeutics to reach diseased tissue without damaging normal brain tissue ...
... , We,ve all heard examples of animal altruism: Dogs caring ... mates to the surface. Now, a study led by the ... The researchers looked at corn, in which each fertilized ... bit of tissue known as endosperm that feeds the embryo ...
... FAIRFAX, Va.The Society of Interventional Radiology and Society for ... prospective study to evaluate the use of inferior vena ... The studyalong with the formation of the IVC Filter ... August 2010 FDA medical alert detailing the possibility that ...
Cached Biology News:Propping open the door to the blood brain barrier 2Can plants be altruistic? You bet, says new CU-Boulder-led study 2Can plants be altruistic? You bet, says new CU-Boulder-led study 3Medical societies to launch large-scale study on vein filter use 2
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
cysteine and glycine-rich protein 2,...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
Biology Products: